Scientists develop potentially therapeutic gel, which detects nitric oxide, absorbs excess fluids and delivers drugs

October 11, 2017
Gel to fight rheumatoid arthritis
IBS scientists developed a hydrogel made of polymeric acrylamide (blue spaghetti) linked with crosslinkers (black), which can accommodate drug molecules (purple stars) within its mesh (grey). In the presence of nitric oxide (red), the linker is cleaved and the drug molecules can be released. At the same time, the gel absorbs fluid from the surroundings and swells in size. Credit: Park J. et al, Advanced Materials (2017)

IBS scientists at the Center for Self-Assembly and Complexity, within the Institute for Basic Science (IBS), invented a hydrogel to fight rheumatoid arthritis and other diseases. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs.

Rheumatoid arthritis (RA) is a long-term that causes inflammation and deformity of the joints, and affects about 1 percent of the world population. In this autoimmune condition, the body's immune system attacks the soft tissue of the joints, leading to an accumulation of synovial fluid. While this clear fluid lubricates and nourishes the joints, its excess causes swelling and pain.

Immune cells at the inflamed are the predominant source of (NO), a gas with various physiological functions. "Nitric oxide is like a double-edge sword. It regulates inflammation and protects our body by killing external pathogens. However, when in excess, it is toxic and may cause RA, as well as other autoimmune diseases, cardiovascular diseases, and cancer," explains the group leader, KIM Won Jong. Current RA treatments are based on anti-inflammatory drugs that relieve pain and inflammation, but IBS scientists tried a more challenging approach by targeting NO itself. NO is a transient gas, which stays in circulation for less than 10 seconds, before binding to other molecules.

The research team developed a gel responsive to such fugitive molecules, using acrylamide as a base material and a new crosslinker to keep it in place. Unlike the monomeric form, polymeric acrylamide hydrogel has little toxicity and can contain a large amount of water. In addition, the cross-linking agent (NOCCL) forms bridges between the acrylamide molecules creating a net, which can trap inside. When NO cleaves the NOCCL bridges, the gel changes its structure, frees the drug and absorbs new liquid.

Although this is a preliminary study, the team confirmed that NOCCL cross-linking agent can selectively and sensitively react with NO. The scientists are now working on a nano-sized hydrogel in a RA mouse model. Moreover, these type of hydrogels could be useful for other diseases characterized by overexpression of NO, or maybe even as environmental sensors, since NO is also a polluting gas emitted in vehicle exhaust.

Explore further: Scientists discover new mechanism that leads to inflammation in rheumatoid arthritis

Related Stories

Cartilage actively contributes to arthritis

September 12, 2014

Melbourne researchers have discovered that cartilage plays an active role in the destruction and remodelling of joints seen in rheumatoid arthritis, rather than being an 'innocent bystander' as previously thought.

Recommended for you

Life's building blocks observed in spacelike environment

December 12, 2017

Where do the molecules required for life originate? It may be that small organic molecules first appeared on earth and were later combined into larger molecules, such as proteins and carbohydrates. But a second possibility ...

Teaching antibiotics to be more effective killers

December 12, 2017

Research from the University of Illinois at Chicago suggests bond duration, not bond tightness, may be the most important differentiator between antibiotics that kill bacteria and antibiotics that only stop bacterial growth.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.